Today: 13 January 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences Corp. (NASDAQ: AVXL) is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex (also known as blarcamesine / ANAVEX®2-73) in Alzheimer’s disease—an outcome that investors had been
12 December 2025
····
Rocket Lab (RKLB) Stock Jumps as Neutron “Hungry Hippo” Clears a Key Milestone — Latest News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

Rocket Lab (RKLB) Stock Jumps as Neutron “Hungry Hippo” Clears a Key Milestone — Latest News, Forecasts, and What Investors Are Watching (Dec. 12, 2025)

(SEO): Rocket Lab (NASDAQ: RKLB) is rallying after a major Neutron reusability milestone and a busy launch cadence. Here’s the latest news, analyst forecasts, and key risks as of Dec. 12, 2025. Published: December 12, 2025Company: Rocket Lab Corporation (NASDAQ:
12 December 2025
····
First Majestic Silver (AG) Stock News Today (Dec. 12, 2025): Silver’s Record Run Fuels Volatility, Convertible Notes Refinancing, and Fresh Analyst Targets

First Majestic Silver (AG) Stock News Today (Dec. 12, 2025): Silver’s Record Run Fuels Volatility, Convertible Notes Refinancing, and Fresh Analyst Targets

First Majestic Silver Corp. (NYSE: AG , TSX: AG ) is ending the week in the center of one of the most explosive precious-metals backdrops in years. On Friday, December 12, 2025 , AG shares swung sharply—trading around $15.77 after
12 December 2025
····
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward
12 December 2025
····
1 … 368 369 370 371 372 … 562
Go toTop